<DOC>
	<DOCNO>NCT01231347</DOCNO>
	<brief_summary>AMG 479 investigational fully human monoclonal antibody target type 1 insulin-like growth factor receptor ( IGF-1R ) . Signaling IGF-1R play important role regulation cell growth survival . Gemcitabine administer day 1 , 8 15 28 day cycle , AMG 479 placebo administer day 1 15 28 day cycle , administer intravenously . The primary purpose study determine AMG 479 gemcitabine improve overall survival compare placebo gemcitabine .</brief_summary>
	<brief_title>QUILT-2.014 : Gemcitabine AMG 479 Metastatic Adenocarcinoma Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Untreated metastatic adenocarcinoma pancreas Adequate hematologic , renal liver function Eastern Cooperative Oncology Group ( ECOG ) 0 1 Prior chemotherapy radiotherapy pancreatic cancer Central nervous system metastases External biliary drain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>metastatic</keyword>
	<keyword>jaundice</keyword>
</DOC>